Efficacy and safety of taxane plus ramucirumab for advanced gastric cancer after chemotherapy plus nivolumab.

ABSTRACT:

Background and purpose

Taxane plus ramucirumab (RAM) is the standard second-line treatment for advanced gastric cancer (AGC). However, data on second-line therapy following first-line treatment with nivolumab remains limited. This study aimed to evaluate the efficacy, safety, and prognostic factors of taxane plus RAM in patients with advanced AGC who previously received chemotherapy plus nivolumab.

Materials and methods

We collected data from AGC patients at multiple institutions who received taxane plus RAM after failure of chemotherapy plus nivolumab. All patients received first-line chemotherapy with nivolumab before December 2022.

Results

In total, 51 patients received taxane plus RAM (41 received paclitaxel plus RAM, and ten received nab-paclitaxel plus RAM). The

SUBMITTER: Matsumoto T 

PROVIDER: S-EPMC12328655 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature